Clinical Trial Update: Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a pemetrexed monotherapy dosing schedule for locally advanced or metastatic non-small cell lung cancer. Results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2009-10-12